Biomedic Acetaminophen with Codeine: Recall Due To Missing Child-Resistant Packaging
- Starting date:
- September 28, 2014
- Posting date:
- September 28, 2014
- Type of communication:
- Drugs, Affects children, pregnant or breast feeding women
- Source of recall:
- Health Canada
- Improper Safety Mechanisms
- General Public
- Identification number:
- Products affected
- What you should do
- Who is affected
- Media enquiries
- Public enquiries
- Send us your feedback
- What Health Canada is doing
Teva Canada Limited, in consultation with Health Canada, is recalling one lot (#669745) of Biomedic Acetaminophen with Codeine (30 caplets with 300 mg acetaminophen and 8 mg codeine) due to missing child-resistant packaging.
Biomedic Acetaminophen with Codeine (30 caplets) (DIN 02143933), lot #669745
What you should do
- Return bottles of Biomedic Acetaminophen with Codeine (30 caplets) from the recalled lot to the location where you purchased it.
- Keep all medication out of reach of children.
- Report any adverse reactions to Health Canada.
Who is affected
This product poses a risk to children who could open the bottle and ingest the bottle’s contents. Codeine is not recommended for use in children under 12 years old. Codeine overdose is associated with breathing problems and potential seizures in predisposed individuals. An acetaminophen overdose can have serious health consequences including liver damage. Early signs of overdose include nausea, vomiting, lethargy and sweating. Liver damage may result in liver failure or death.
The recalled lot was distributed in July 2014 in the provinces of British Columbia and Quebec.
Send us your feedback
- Call toll-free at 1-866-234-2345
- Visit MedEffect Canada's web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.
What Health Canada is doing
Health Canada is monitoring the recall by Teva Canada Ltd. Should new information be identified, Health Canada will provide an update to Canadians.
For more information
Consumers and health professionals wanting more information about this advisory from Health Canada can contact the Public Enquiries Line at 613-957-2991, or toll free at 1-866-225-0709.
Media enquiries related to this Advisory should be directed to Health Canada Media Relations at 613-957-2983.
- Date modified: